MK 1167
Alternative Names: MK-1167Latest Information Update: 19 Apr 2024
At a glance
- Originator Merck Sharp & Dohme
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 28 Mar 2024 Phase-I clinical trials in Alzheimer's disease (Adjunctive treatment) in USA (PO) (NCT06285240)
- 29 Feb 2024 Merck Sharp & Dohme plans a phase I trial for Alzheimer's disease (Adjunctive treatment) (PO) in March 2024 (NCT06285240)
- 24 Oct 2023 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Japan (PO) (jRCT2031230399)